How to manage lupus nephritis in my 31-year-old cousin?

Question

Hello doctor,

I have a cousin who is 31 years old. She was diagnosed with lupus nephritis, Class III, last year, confirmed by a kidney biopsy. She is currently on Mycophenolate mofetil and corticosteroids, and her serum creatinine has remained stable at 1.1 mg/dL. However, her urine still shows 2+ protein, and her anti-dsDNA levels remain elevated.

Everyone is trying to stay hopeful, but there is concern that the disease may still be active and silently causing kidney damage. Does this mean that the current treatment is not sufficient? What other treatment options can be considered before the condition worsens?

Kindly advise.

Answer 1

Hello,

Welcome to icliniq.com.

I can understand why this situation feels frightening, and it is completely natural to worry when laboratory results are not fully controlled, even though she seems clinically stable. Lupus nephritis can be emotionally exhausting for patients and families because improvement is often slow and does not always follow a straight course.

The reassuring aspect is that her kidney function is stable, with a serum creatinine level of 1.1 milligrams per deciliter (mg/dL), which indicates that there is no obvious ongoing loss of kidney filtration at present. Persistent two-plus protein in the urine and an elevated anti–double–stranded Deoxyribonucleic acid (anti-dsDNA) level can suggest that some degree of immune activity may still be present, but this does not automatically mean that the kidneys are being silently damaged or that the treatment has failed.

In many patients with Class III lupus nephritis, proteinuria and antibody levels lag behind clinical improvement and may take many months, or even longer, to normalize, especially during the first year of treatment.

What usually matters most when deciding whether therapy is adequate is the overall trend rather than a single laboratory snapshot. Physicians assess whether urine protein levels are gradually decreasing, whether serum creatinine remains stable, whether complement levels are improving, and whether symptoms such as swelling or rising blood pressure are present.

If proteinuria persists after an adequate duration of treatment, options to consider before the condition worsens include optimizing the dose of Mycophenolate mofetil, ensuring strict medication adherence, adding or maximizing kidney-protective medicines such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and reassessing corticosteroid tapering to ensure that inflammation is fully controlled.

In some cases, clinicians may consider adding or switching immunosuppressive therapy, such as calcineurin inhibitors including Tacrolimus or Voclosporin, or using biologic therapy such as Belimumab, depending on treatment response and side effect profile. A repeat kidney biopsy is sometimes considered if there is uncertainty about whether ongoing proteinuria is due to active inflammation or scarring from prior damage.

It is important for her to remain under close follow-up with both nephrology and rheumatology specialists, continue regular urine protein measurements, blood tests, and blood pressure monitoring, and avoid triggers such as infections or missed medications.

Many individuals with Class III lupus nephritis achieve long-term kidney stability with careful adjustment of therapy, even if laboratory values take time to settle. Staying hopeful is reasonable, as stable kidney function is a strong positive sign, and several effective treatment options remain available if additional disease control is needed.

I hope you are satisfied with my answer. For further queries, you can consult me at iCliniq.

Thank you.